Weight

• Mistral AI is seeking $3.5 billion in funding to advance its goals of European AI sovereignty and enterprise-grade technology. • The company has promised to release a new open weights model this summer to compete in the evolving AI landscape. • This strategic move comes amid rising demands for sovereign technology and follows disruptions to other models, such as those from Anthropic.

• Lizzo appeared at the 2026 BET Awards wearing a sparkling sheer gown, drawing significant public attention to her dramatic weight loss. • The appearance serves as a public showcase of the singer's ongoing body transformation journey. • This event highlights Lizzo's evolving relationship with her public image and her choice to share her health journey through high-profile fashion statements.

Regulator approval means patients who meet criteria such as having obesity will be able to purchase pills with private prescriptionPatients will soon be able to buy the Wegovy weight-loss pill, the medicines regulator announced today.It is the first GLP-1 receptor agonist tablet for weight-loss to be approved by the Medicines and Healthcare products Regulatory Agency (MHRA), making the UK the third country to authorise the pills, behind the US and the United Arab Emirates. Continue reading...

• Shoptalk Europe unveiled five major predictions for the future of European retail during its 2026 event in Barcelona. • The forecast identifies AI shopping agents, the rise of weight-loss drugs, a "recommerce boom," personalized physical stores, and revamped supply chain planning as primary drivers of change. • These trends are expected to fundamentally reshape the retail industry over the next decade, impacting how consumers shop and how businesses operate.

New research suggests GLP-1 users are buying fewer snacks and treats such as crisps and chocolateBusiness live – latest updatesWeight-loss drugs are saving users’ households more than £400 a year on grocery bills, according to new research, which found use of GLP-1s has nearly tripled in the past two years to 1.9 million adults.Just more than 6.3% of households in Great Britain now include at least one GLP-1 user, according to the survey from Worldpanel by Numerator. This marks a sharp rise from 4.1% of households in 2025 and 2.3% in 2024. Continue reading...

Price of dairy product has risen fivefold after users of GLP-1 medications advised to increase protein consumptionThe growing popularity of weight-loss drugs has fuelled global demand for whey protein, sparking concerns among industry experts over a potential shortage.The price of whey has risen fivefold to record levels as companies race to secure supplies amid a boom driven by growing use of GLP-1 drugs, such as Mounjaro, which often require higher protein intake to preserve muscle mass. Continue reading...

Experts say results from trial of new triple hormone drug for type 2 diabetes are striking but further tests neededA new triple-action weekly jab for type 2 diabetes could significantly reduce blood sugar and body weight, according to phase 3 trial results. Patients in the trial receiving weekly retatrutide injections for 40 weeks lost more than four times as much weight as those on placebo, while the average drop in long-term blood sugar (HbA1c) was more than twice that of the placebo.The triple hormone drug mimics three gut hormones that help control your appetite, blood sugar and metabolism: GLP-1, GIP and glucagon. Unlike other diabetes medications such as Ozempic and Wegovy, which primarily target the GLP-1 pathway to suppress appetite, or Mounjaro, which contains GLP-1 plus GIP to control blood-sugar levels, retatrutide also engages the glucagon receptor, which helps increase energy expenditure. Continue reading...